Vagistat-1 vaginal ointment is now approved for OTC use

April 1997

Vagistat-1 vaginal ointment is now approved for OTC use. It's the first SINGLE-dose OTC treatment for vaginal yeast infections.

Vagistat-1 (tioconazole) is comparable to using Terazol 3 (terconazole) or Monistat 7 (miconazole).

Tioconazole levels persist for 3 to 5 days after one dose.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Treatment of systolic heart failure
Osteoporosis Fosamax (alendronate) will soon be promoted to PREVENT osteoporosis in postmenopausal women
Osteoporosis New drug for bone loss called Skelid (SKEL-id, tiludronate)
Interactions Warn people about drug interactions with grapefruit
Dermatology Nitroglycerin ointment for chronic anal fissures
Dermatology New topical tretinoin products for acne
Dermatology Proscar (finasteride) stimulating hair growth
Asthma New asthma guidelines
Asthma Too many asthmatics still AREN'T using inhaled steroids
Hypertension Microzide, a new low-dose HCTZ capsule
Infectious Diseases SINGLE dose antibiotic for bladder infections called Monurol (fosfomycin)
Infectious Diseases Zagam (sparfloxacin), a new quinolone antibiotic
Infectious Diseases Sporanox (itraconazole) ORAL SOLUTION
Infectious Diseases Crixivan at their local pharmacy
Anticoagulants First HOME monitor for patients on warfarin (Coumadin)
Women's Health New estrogen patches will be hitting the market
Women's Health Vagistat-1 vaginal ointment is now approved for OTC use
Cholesterol Cholestin, a dietary supplement to lower cholesterol
Hypertension Microzide, a new low-dose HCTZ capsule